A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket. A series of experiments employing MS, molecular modeling, site-directed mutagenesis, and 14 C-labeling studies in viable cells unequivocally demonstrate that these compounds selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773. While the compounds are essentially nonreactive in solution, they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket. The molecular orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as determined from docking experiments in a homology-built molecular model of the ATP site. Evidence is also presented to indicate that the compounds interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study. Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses. The activity profile for this compound is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.Considerable evidence has emerged, both preclinically and clinically, over the last decade to implicate the epidermal growth factor (EGF) receptor (EGFr) and erbB2 in the development, progression, and severity of certain human cancers. More recently, however, it has become clear that these receptors can intensify the transforming signal in a synergistic manner through their ability to form both homo-and heterodimers (1-7). Coexpression of the EGFr and erbB2 to levels where either receptor alone had little effect was highly transforming (8 -10). The association between overexpression and͞or constitutive activation of members of the type 1 receptor TK family (11) as well as coexpression of their cognate ligands (EGF, the heregulin family, transforming growth factor-␣, betacellulin) and transformation has been well established in many primary tumors. In particular, high expression levels of the EGFr and erbB2 have been frequently observed in breast, prostate, ovarian, and various squamous cell carcinomas in which overexpression positively correlates with shortened survival times and increased relapse rates (12-21).Over the past decade drug discovery efforts have produced a wide variety of chemical structures, generated either by synthetic means or as fermentation products, that reportedly inhibit purified or partially purified preparations of the EGFr tyrosine ki...

No abstract

SUMMARYTwo kappa opiate agonists 1 and 2 have been labeled from bromo-I 1-14C] -acetic acid and sodium [ l-14C]acetate respectively.

SWMARY CI-911 [dihydro-l~-pyrrolizine-3,5(2~,6~)-dione] (l), a new c o g n i t i o n a c t i v a t i n g a g e n t , was r a d i o l a b e l e d w i t h 14C and 3H.s y n t h e s i s was accomplished using nitromethane-14C as t h e s t a r t i n g material t o result i n an o v e r a l l radiochemical y i e l d of 9.2%. r y of a n a t t e n t i o n enhancing a g e n t , CI-844l, and a n a n t i c o n f u s i o n a l a g e n t , pramiracetam2 (CI-879), which h a s been l a b e l e d . e f f o r t s have t u r n e d t o t h e i n v e s t i g a t i o n o f compounds w i t h b r o a d e r d o s e response c u r v e s and w i t h a c t i v i t y in b e h a v i o r a l t e s t s s u g g e s t i v e of memory enhancement.These e f f o r t s have r e s u l t e d in t h e d i s c o v e r y of CI-911, dihydro-l~-pyrrolizine-3,5( 2g,6&)-dione4 (1).Recently our CI-911 w a s found t o have a n e x t r a o r d i n a r i l y wide d o s e response curve i n a n amnesia r e v e r s a l t e s t i n mice.